$VRNA

Galectin Therapeutics (GALT) shared updated results for its drug Belapectin targeting MASH Cirrhosis and Portal Hypertension, revealing some promising outcomes that suggest the drug may effectively reduce portal pressure. However, investor sentiment appears cautious as the trials are still early-stage, and definitive results are pending. Analysts are divided on the implications for GALT's long-term prospects in the liver disease market. As investors await further clinical trial data, volatility in GALT's stock is likely in the short-term. Overall, the news has the potential to excite some investors while keeping the risk factor high for others.